Details of Disease

General Information of Disease (ID: DISFPT78)

• Disease Name: Anthrax
• Synonyms: anthrax disease; Bacillus anthracis disease or disorder; Bacillus anthracis caused disease or disorder; Bacillus anthracis infectious disease; anthrax
• Disease Class: 1B97: Anthrax
• Definition: An infection caused by Bacillus anthracis bacteria. It may affect the lungs, gastrointestinal tract, or skin. Patients with lung infection present with fever, headaches, cough, chest pain and shortness of breath. Patients with gastrointestinal infection present with nausea, vomiting and bloody diarrhea. Patients with skin infection develop blisters and ulcers.|Editor note: DOID says skin disease but we suppress this as it would be identical to subclass skin anthrax
• Disease Hierarchy:
  DISG0H9V: Bacillaceae infectious disease
  DIS8ZVFW: Primary bacterial infectious disease
  DISEM33Q: Infectious disease
  DISFPT78: Anthrax
• ICD Code:
  ICD-11: ICD-11: 1B97
  ICD-9: ICD-9: 22
  Expand ICD-11: '1B97
  Expand ICD-10: 'A22; 'A22.0; 'A22.1; 'A22.2; 'A22.7; 'A22.8; 'A22.9
  Expand ICD-9: 22
• Disease Identifiers:
  MONDO ID: MONDO_0005119
  MESH ID: D000881
  UMLS CUI: C0003175
  MedGen ID: 8110
  SNOMED CT ID: 409498004

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 8 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Ciprofloxacin XR	DM2NLS9	Approved	Small molecular drug	[1]
Doxycycline	DM7ICNU	Approved	Small molecular drug	[2]
ETI-204	DMBIYNH	Approved	Antibody	[3]
Fusidic Acid	DMWVCF3	Approved	Small molecular drug	[4]
Levofloxacin	DMS60RB	Approved	Small molecular drug	[5]
Norfloxacin	DMIZ6W2	Approved	Small molecular drug	[6]
Ofloxacin	DM0VQN3	Approved	Small molecular drug	[7]
Raxibacumab	DM7QG0M	Approved	Monoclonal antibody	[8]

This Disease is Treated as An Indication in 12 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AV7909	DM42N5V	Phase 3	Vaccine	[9]
Benzylpenicillin	DMS9503	Phase 3	Small molecular drug	[10]
AV-7909	DMUS9CO	Phase 2	NA	[11]
NuThrax	DMGDWUF	Phase 2	NA	[12]
RPA-102	DMZNNS7	Phase 2	NA	[13]
SparVax recombinant protective antigen anthrax vaccine	DM9VADK	Phase 2	NA	[14]
Anthrax transdermal vaccine	DMLLAWW	Phase 1	NA	[15]
BW-1010	DMJPN84	Phase 1	Vaccine	[16]
NasoShield	DMTQ35M	Phase 1	Vaccine	[17]
Px563L	DMBEE3U	Phase 1	NA	[12]
RPA gene based adenovirus 4 vector vaccine	DMW1THE	Phase 1	NA	[18]
Valtorim	DMQBV8E	Phase 1	NA	[19]

This Disease is Treated as An Indication in 1 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Anthrax DNA vaccine	DMCEKT2	Discontinued in Phase 1	NA	[20]

This Disease is Treated as An Indication in 3 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
F24F2	DM29M4R	Preclinical	Antibody	[21]
F26G3	DM2GEHA	Preclinical	Antibody	[21]
F26G4	DMAVQ2X	Preclinical	Antibody	[21]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 3 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ANTXR2	TTOD34I	Limited	Biomarker	[22]
NLRP1	TTQX29T	Strong	Biomarker	[23]
PRCP	TTTJZ4M	Strong	Biomarker	[24]

This Disease Is Related to 13 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ANTXR1	OT5W1GPC	Strong	Genetic Variation	[25]
ARAP3	OTUWZTH7	Strong	Biomarker	[26]
CNTNAP1	OT5Y03EU	Strong	Genetic Variation	[27]
FBRS	OTUVH446	Strong	Biomarker	[28]
FBXO8	OTZNGJGW	Strong	Biomarker	[28]
IMMT	OTBDSLE7	Strong	Biomarker	[29]
ITIH4	OT460OO1	Strong	Altered Expression	[30]
KIF1C	OTKYLP1Q	Strong	Genetic Variation	[31]
MAP2K3	OTI2OREX	Strong	Biomarker	[32]
NLRC4	OTAIA3NA	Strong	Biomarker	[33]
PAGR1	OTXR5PQ8	Strong	Biomarker	[34]
PPIP5K2	OTO61OBN	Strong	Biomarker	[35]
STT3A	OTDPS6AV	Strong	Biomarker	[36]

References

• [1] A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
• [2] Doxycycline FDA Label
• [3] 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
• [4] Cationic quaternized aminocalix[4]arenes: cytotoxicity, haemolytic and antibacterial activities. Int J Pharm. 2013 Dec 15;458(1):25-30.
• [5] Levofloxacin FDA Label
• [6] Norfloxacin FDA Label
• [7] Ofloxacin FDA Label
• [8] Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011 Apr 1;186(7):4234-43.
• [9] ClinicalTrials.gov (NCT03877926) VELOCITY: An Anthrax Vaccine Clinical Study. U.S. National Institutes of Health.
• [10] Human Anthrax: Update of the Diagnosis and Treatment. Diagnostics (Basel). 2023 Mar 10;13(6):1056.
• [11] ClinicalTrials.gov (NCT01770743) A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels. U.S. National Institutes of Health.
• [12] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [13] ClinicalTrials.gov (NCT00100724) Trial of rPA-102 Vaccine in Healthy Adult Volunteers. U.S. National Institutes of Health.
• [14] Clinical pipeline report, company report or official report of PharmAthene.
• [15] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024214)
• [16] ClinicalTrials.gov (NCT04148118) A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Anthrax Vaccine in Healthy Adults (IN NE-rPA). U.S. National Institutes of Health.
• [17] ClinicalTrials.gov (NCT03352466) NasoShield Study of Safety and Immunogenicity (NasoShield). U.S. National Institutes of Health.
• [18] Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study. Lancet Infect Dis. 2013 Mar;13(3):238-50.
• [19] More Than 450 Medicines in Development for Rare Diseases. Pharmaceutical Research and Manufacturers of America report. 2013.
• [20] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018519)
• [21] Protective and immunochemical activities of monoclonal antibodies reactive with the Bacillus anthracis polypeptide capsule. Infect Immun. 2007 Jan;75(1):152-63.
• [22] Capillary morphogenesis protein 2 is a novel prognostic biomarker and plays oncogenic roles in glioma.J Pathol. 2018 Jun;245(2):160-171. doi: 10.1002/path.5062. Epub 2018 Apr 2.
• [23] NLRP1 - One NLR to guard them all.EMBO J. 2019 Jul 1;38(13):e102494. doi: 10.15252/embj.2019102494. Epub 2019 Jun 12.
• [24] Polysaccharide PCP-I isolated from Poria cocos enhances the immunogenicity and protection of an anthrax protective antigen-based vaccine.Hum Vaccin Immunother. 2020 Jul 2;16(7):1699-1707. doi: 10.1080/21645515.2019.1675457. Epub 2019 Dec 6.
• [25] A biallelic ANTXR1 variant expands the anthrax toxin receptor associated phenotype to tooth agenesis.Am J Med Genet A. 2018 Apr;176(4):1015-1022. doi: 10.1002/ajmg.a.38625. Epub 2018 Feb 13.
• [26] EST-based genome-wide gene inactivation identifies ARAP3 as a host protein affecting cellular susceptibility to anthrax toxin.Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17246-51. doi: 10.1073/pnas.0407794101. Epub 2004 Nov 29.
• [27] Genetic characteristics of Bacillus anthracis isolated from northwestern China from 1990 to 2016.PLoS Negl Trop Dis. 2018 Nov 12;12(11):e0006908. doi: 10.1371/journal.pntd.0006908. eCollection 2018 Nov.
• [28] Yeast-hybrid based high-throughput assay for identification of anthrax lethal factor inhibitors.Biochem Biophys Res Commun. 2011 Jan 7;404(1):517-22. doi: 10.1016/j.bbrc.2010.12.015. Epub 2010 Dec 6.
• [29] Anthrax: a motor protein determines anthrax susceptibility.Curr Biol. 2001 Nov 13;11(22):R905-6. doi: 10.1016/s0960-9822(01)00550-4.
• [30] Systematic mutational analysis of human neutrophil -defensin HNP4.Biochim Biophys Acta Biomembr. 2019 Apr 1;1861(4):835-844. doi: 10.1016/j.bbamem.2019.01.007. Epub 2019 Jan 15.
• [31] Quickening the pace of anthrax research: three advances point towards possible therapies.Trends Microbiol. 2002 Feb;10(2):58-62. doi: 10.1016/s0966-842x(01)02294-6.
• [32] Bacillus anthracis' lethal toxin induces broad transcriptional responses in human peripheral monocytes.BMC Immunol. 2012 Jul 2;13:33. doi: 10.1186/1471-2172-13-33.
• [33] Inflammasomes: guardians of cytosolic sanctity.Immunol Rev. 2009 Jan;227(1):95-105. doi: 10.1111/j.1600-065X.2008.00730.x.
• [34] NAD+-Glycohydrolase Promotes Intracellular Survival of Group A Streptococcus.PLoS Pathog. 2016 Mar 3;12(3):e1005468. doi: 10.1371/journal.ppat.1005468. eCollection 2016 Mar.
• [35] Structure, Function and Evolution of Clostridium botulinum C2 and C3 Toxins: Insight to Poultry and Veterinary Vaccines.Curr Protein Pept Sci. 2017;18(5):412-424. doi: 10.2174/1389203717666161201203311.
• [36] Trimethyl Chitosan Nanoparticles Encapsulated Protective Antigen Protects the Mice Against Anthrax.Front Immunol. 2018 Mar 20;9:562. doi: 10.3389/fimmu.2018.00562. eCollection 2018.